# Long Term Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension

Study · id `cardio:ct-nct01237873` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01237873](<https://clinicaltrials.gov/study/NCT01237873>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01237873

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 150 participants.

## Technical summary

Registry record NCT01237873. Allocation not applicable; no masking; primary purpose treatment. Start 2011-01 (registry gives no type); primary completion 2012-02 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 150 participants (enrolled count; ClinicalTrials.gov record NCT01237873, source copy `cardio:ctgov-nct01237873-2017-02-23`, retrieved 2026-10-26)
- Start date: 2011-01 (registry gives no type) (ClinicalTrials.gov record NCT01237873, source copy `cardio:ctgov-nct01237873-2017-02-23`, retrieved 2026-10-26)
- Primary completion: 2012-02 (actual) (ClinicalTrials.gov record NCT01237873, source copy `cardio:ctgov-nct01237873-2017-02-23`, retrieved 2026-10-26)
- Completion: 2012-02 (actual) (ClinicalTrials.gov record NCT01237873, source copy `cardio:ctgov-nct01237873-2017-02-23`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT01237873, source copy `cardio:ctgov-nct01237873-2017-02-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01237873-2017-02-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: Long Term Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension
- Condition: Essential Hypertension
- Intervention (Drug): Ali/Amlo 150/2.5 mg
- Lead sponsor: Novartis Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

## Provenance

Content hash: d5baf9a3cfa4734960555c43cbcc8110b92c3a1e05d4b5644f1c5219c4b8c3e8
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
